Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. The company offers cerebrum, a small molecule platform for CNS small molecule therapies and solidus, an antisense oligonucleotide platform to discover and develop antisense oligonucleotide. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; vormatrigine, a small molecule targeting the hyperexcitable state of sodium-channels in the brain to treat focal onset epilepsy; relutrigine for the treatment of developmental and epileptic encephalopathies; PRAX-020; and PRAX-050. In addition, the company develops elsunersen, a clinical-stage ASO designed to regulate NaV1.2 expression for the treatment of SCN2A-DEE; PRAX-080; PRAX-090; and PRAX-100. It has a license agreement with RogCon Inc.; and research collaboration and license agreement with Ionis Pharmaceuticals, Inc. The company was incorporated in 2015 and is based in Boston, Massachusetts.
Metrics to compare | PRAX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPRAXPeersSector | |
---|---|---|---|---|
P/E Ratio | −4.2x | −0.5x | −0.5x | |
PEG Ratio | −0.09 | −0.01 | 0.00 | |
Price/Book | 1.7x | 1.1x | 2.6x | |
Price / LTM Sales | 90.2x | 10.2x | 3.0x | |
Upside (Analyst Target) | 127.9% | 39.6% | 56.3% | |
Fair Value Upside | Unlock | 8.5% | 10.0% | Unlock |